Published in Arterioscler Thromb Vasc Biol on August 01, 2000
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation (2010) 3.37
Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol (2002) 1.80
Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest (2001) 1.31
Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation (2008) 1.19
From proliferation to proliferation: monocyte lineage comes full circle. Semin Immunopathol (2014) 0.93
Adipose lineage specification of bone marrow-derived myeloid cells. Adipocyte (2012) 0.88
HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord (2003) 0.82
Infection with Toxoplasma gondii increases atherosclerotic lesion in ApoE-deficient mice. Infect Immun (2004) 0.81
Cyclooxygenase products and atherosclerosis. Drug Discov Today Ther Strateg (2008) 0.79
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 11.53
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell (1996) 11.02
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature (1997) 8.38
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 8.33
Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (1992) 7.09
Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest (1991) 6.50
Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A (1984) 6.01
RXR beta: a coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell (1991) 5.89
Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest (1989) 5.75
Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A (1989) 5.65
Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. Nat Cell Biol (2001) 5.37
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev (1999) 4.92
Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A (1991) 4.56
Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science (1998) 4.55
Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A (1981) 4.50
Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 4.32
The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell (1991) 4.27
Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A (1987) 4.10
Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem (1997) 3.91
Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature (1995) 3.90
15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A (2000) 3.89
Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev (1998) 3.79
Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A (1987) 3.55
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation (1999) 3.53
Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest (2000) 3.51
Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell (2000) 3.47
Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature (1988) 3.42
Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet (1999) 3.34
Serum cholesterol. Doing the right thing. Circulation (1993) 3.16
ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb (1994) 3.11
Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol (1999) 3.11
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1998) 2.93
The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci U S A (2000) 2.92
Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev (1999) 2.92
Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol (1991) 2.92
Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor. Nat Genet (1994) 2.91
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2001) 2.85
Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A (1988) 2.83
Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest (1999) 2.81
Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem (2001) 2.70
Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis (1990) 2.70
Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature (1998) 2.65
Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci U S A (1997) 2.63
SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell (1998) 2.60
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis (1983) 2.48
Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb (1994) 2.47
A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol (1996) 2.47
A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem (1989) 2.45
Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature (1994) 2.43
A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J (1983) 2.42
Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest (1986) 2.38
Reconstitution of licensed replication origins on Xenopus sperm nuclei using purified proteins. BMC Biochem (2001) 2.36
Structure of the transition state for folding of a protein derived from experiment and simulation. J Mol Biol (1996) 2.36
Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest (1991) 2.35
Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis (1986) 2.32
Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1996) 2.32
Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A (1983) 2.25
Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A (1990) 2.23
Signal-specific co-activator domain requirements for Pit-1 activation. Nature (1998) 2.22
Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol (2001) 2.20
Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A (2000) 2.17
Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol (2000) 2.12
Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Genes Dev (1993) 2.11
Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci U S A (1985) 2.11
Effect of natural genetic variation on enhancer selection and function. Nature (2013) 2.10
Differential use of CREB binding protein-coactivator complexes. Science (1998) 2.10
Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev (2001) 2.09
Receptor-dependent and receptor-independent degradation of low density lipoprotein in normal rabbits and in receptor-deficient mutant rabbits. J Biol Chem (1982) 2.06
Small espin: a third actin-bundling protein and potential forked protein ortholog in brush border microvilli. J Cell Biol (1998) 2.06
Oral topical decontamination for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect (2013) 2.05
Uptake and degradation of low density lipoprotein by swine arterial smoot muscle cells with inhibition of cholesterol biosynthesis. Biochim Biophys Acta (1976) 2.05
Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem (1998) 2.02
Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. Proc Natl Acad Sci U S A (1995) 1.95
beta-Thalassemia in Chinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects. Proc Natl Acad Sci U S A (1984) 1.92
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer (2010) 1.90
Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet (1994) 1.88
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol (1997) 1.87
The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med (2000) 1.87
Uptake of high-density lipoprotein-associated apoprotein A-I and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. J Biol Chem (1985) 1.86
Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci (2001) 1.82
Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis (1987) 1.80
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest (1991) 1.79
Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol (1999) 1.78